Instil Bio, Inc. Common Stock (TIL) Stock Price
TILStock
$5.91−70.71%52W
Market Cap$40.08M
P/E—
PEG Ratio—
Div yield—
Beta1.92
TIL Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-39.88%
Price vs S&P 500 (4W)-15.08%
VGM Score36.23
TIL Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.35 | -$0.63 | -80.00%(-$0.28) | |
| Q1 2026 | -$0.59 | -$0.62 | -5.08%(-$0.03) | |
| Q4 2025 | -$3.78 | -$0.97 | +74.34%(+$2.81) | |
| Q3 2025 | -$3.04 | -$1.75 | +42.43%(+$1.29) | |
| Q2 2025 | -$2.44 | -$2.88 | -18.03%(-$0.44) |
TIL Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.00
4.00
4.00
4.00
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
TILInstil Bio, Inc. Common Stock | — | — | D | — | — | — | — | $5.91 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
About Instil Bio, Inc. Common Stock
Instil Bio is a clinical-stage biopharmaceutical company developing cell therapy treatments for cancer using tumor infiltrating lymphocytes (TILs). The company's proprietary CoStAR platform enables genetic engineering of TILs to enhance their recognition of tumor-associated antigens. Its lead candidate, ITIL-306, is in clinical development for multiple solid tumors including ovarian, uterine, non-small cell lung cancer, and renal cancer.